CN103948657A - Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl - Google Patents
Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl Download PDFInfo
- Publication number
- CN103948657A CN103948657A CN201410170990.3A CN201410170990A CN103948657A CN 103948657 A CN103948657 A CN 103948657A CN 201410170990 A CN201410170990 A CN 201410170990A CN 103948657 A CN103948657 A CN 103948657A
- Authority
- CN
- China
- Prior art keywords
- beta
- compound medicine
- herba andrographis
- lactam
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl, which is prepared from the following raw materials in parts by weight: 3-30 parts of beta-lactam antibacterial agent and 5-200 parts of creat. The raw materials are evenly mixed and prepared into powder, tablets, oral liquids or granules, and 0.1-7g of the compound medicine is added to every kilo of feed for livestock and fowl for feeding; and the feed with the compound medicine can reverse the drug resistance of bacteria to antibacterial agents, thereby enhancing the treatment effect of the antibacterial agents, greatly lowering the medicine cost and medicine residue, creating higher economic benefit for farmers and ensuring the human food safety.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, relate in particular to a kind of poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, causes huge economic loss to aquaculture.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents reported colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor, producing the escherichia coli that are separated to tolerate P-levels mycin product fosA3 drug resistant gene in ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings larger economic loss to production, and increases poultry drug residue risk.Therefore, in actual production, need a kind of to no matter whether, the escherichia coli of drug resistance can have the medicine of better therapeutical effect badly, and can shorten treatment course for the treatment of, reduce mortality rate, reducing economic loss and reduce drug residue, is that raiser creates higher economic benefit, also ensures that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug, it can kill antibacterial quickly, overcome antimicrobial drug treatment due to large, the residual height of weak curative effect, consumption and the high defect of cost that drug resistance problem causes, avoided that simple Chinese medicine sterilizing spectrum is narrow, slow problem sterilizes.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug, is made up of the raw material of following weight portion: beta-lactam antimicrobial drug 3-30 part, Herba Andrographis 5-200 part.
Described beta-lactam antimicrobial drug is amoxicillin, ceftriaxone sodium or ceftiofur sodium.
Further, described compound medicine is made up of the raw material of following weight portion: amoxicillin 3-20 part and Herba Andrographis 40-180 part, or ceftiofur sodium 3-25 part and Herba Andrographis 30-190 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Herba Andrographis was pulverized to 60 mesh sieves, then mix with pulverous antimicrobial drug, and be prepared into according to a conventional method powder, tablet, oral liquid or granule.
The drug resistance problem existing for current poultry coli-infection, inventor utilizes Guangxi Special Traditional Chinese Medicine Herba Andrographis and antimicrobial drug composition compound medicine.Studies have shown that, in antimicrobial drug, add after Herba Andrographis, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, add in animal and fowl fodder and feed according to the addition of 0.1-7g principal agent/kg feedstuff, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guarantee food safety simultaneously.
Detailed description of the invention
One, the drug resistance inversion effect research of Herba Andrographis to antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but because the escherichia coli that produce ESBLs drug resistant gene have stronger drug resistance, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Herba Andrographis to antimicrobial drug, on 96 orifice plates, adopt microtest tube doubling dilution, first measure minimal inhibitory concentration and the subinhibitory concentration of Herba Andrographis to product ESBLs and fosA3 drug resistant gene e. coli strains of the e. coli strains of antimicrobial drug to product ESBLs and fosA3 drug resistant gene, then in culture medium, added the Herba Andrographis of subinhibitory concentration to reuse the minimal inhibitory concentration of microtest tube doubling dilution cultivation mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Herba Andrographis and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing diminishes more than 4 times compared with before going down to posterity, can be judged as Herba Andrographis has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.25g/mL) Herba Andrographis goes down to posterity and causes the variation (μ g/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge that Herba Andrographis has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
Preparation Example 1-embodiment 8 in accordance with the following methods: Herba Andrographis was pulverized after 60 mesh sieves, as basic material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Herba Andrographis | Dosage form |
| Embodiment 1 | Amoxicillin 3g | 120g | Tablet |
| Embodiment 2 | Amoxicillin 10g | 90g | Powder |
| Embodiment 3 | Amoxicillin 14g | 40g | Oral liquid |
| Embodiment 4 | Amoxicillin 20g | 180g | Granule |
| Embodiment 5 | Ceftiofur sodium 13g | 190g | Tablet |
| Embodiment 6 | Ceftiofur sodium 15g | 85g | Powder |
| Embodiment 7 | Ceftiofur sodium 3g | 5g | Oral liquid |
| Embodiment 8 | Ceftiofur sodium 25g | 30g | Granule |
Inventor obtains compound medicine product by above-described embodiment and has carried out following experiment:
1, the efficacy experiment of the compound medicine product of embodiment 1-4 gained to chicken escherichia coil disease
Clinical symptoms: Guigang, Guangxi chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.Cultivate by escherichia coli, biochemical test is differentiated, judges that chicken infects for bacillus coli, and pcr amplification, proves to produce the ESBLs drug resistant gene that has TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use embodiment 1 according to the addition administration of 7g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 2g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 0.8g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 2g/kg feedstuff for the 4th group; The 5th group with amoxicillin powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Herba Andrographis according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect that contains Herba Andrographis is better than folk prescription.
2, the efficacy experiment of the meat-type duck diarrhoea of the compound medicine product of embodiment 5-8 gained to 20 ages in days
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.A duck group material feeding is not but long, and the serious duck appearance foot gradually of suffering from diarrhoea is individually soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag muddiness, tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use embodiment 5 according to the addition administration of 3g/kg feedstuff for first group, use embodiment 6 according to the addition administration of 1.3g/kg feedstuff for second group, use embodiment 7 according to the addition administration of 0.5g/kg feedstuff for the 3rd group, use embodiment 8 according to the addition administration of 0.5g/kg feedstuff for the 4th group; The 5th group with ceftiofur sodium powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Herba Andrographis according to the addition administration of 5g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 3 days, and duck group be almost recovered; The 5th group of medication is after 2 days, and duck group DeGrain, much still draws watery stools, contain indigested feedstuff, continue to use 3 days, some improvement a little, but not good thorough, rare watery stools still occurs, raiser cannot drug withdrawal, have to use the compound medicine of embodiment 6 gained instead, continue to use 2 days, just be almost recovered, re-use 1 day, feces all transfers to normally; The 6th group of medication is after 2 days, and duck does not have too large remarkable improvement, continues to use 3 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Herba Andrographis is better than folk prescription to the curative effect of duck diarrhoea.
Claims (4)
1. containing a poultry compound medicine for Herba Andrographis and beta-lactam antimicrobial drug, it is characterized in that, formed by the raw material of following weight portion: beta-lactam antimicrobial drug 3-30 part, Herba Andrographis 5-200 part.
2. the poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug according to claim 1, is characterized in that, described beta-lactam antimicrobial drug is amoxicillin, ceftriaxone sodium or ceftiofur sodium.
3. the poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug according to claim 2, it is characterized in that, described compound medicine is made up of the raw material of following weight portion: amoxicillin 3-20 part and Herba Andrographis 40-180 part, or ceftiofur sodium 3-25 part and Herba Andrographis 30-190 part.
4. according to the poultry compound medicine containing Herba Andrographis and beta-lactam antimicrobial drug described in any one in claim 1-3, it is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410170990.3A CN103948657A (en) | 2014-04-25 | 2014-04-25 | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410170990.3A CN103948657A (en) | 2014-04-25 | 2014-04-25 | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103948657A true CN103948657A (en) | 2014-07-30 |
Family
ID=51326099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410170990.3A Pending CN103948657A (en) | 2014-04-25 | 2014-04-25 | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948657A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138184A (en) * | 2016-08-22 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and amoxicillin |
-
2014
- 2014-04-25 CN CN201410170990.3A patent/CN103948657A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 刘海燕 等: "冬季仔猪流行性腹泻病的防控", 《畜禽业》 * |
| 张国祖 等: "穿心莲水提物与10 种临床常用抗菌药联用的体外抑菌试验", 《中国畜牧兽医》 * |
| 程有才: "家畜交巢(后海)穴注药治验", 《中国兽医科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138184A (en) * | 2016-08-22 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and amoxicillin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103690952A (en) | Compound drug for treating livestock and poultry escherichia coli infected diseases | |
| CN103977090B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and florfenicol | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103989730A (en) | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103977089A (en) | Compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948691A (en) | Red paeonia/sulfamonomethoxine sodium-containing compound medicine for livestock and fowl | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN103933544A (en) | Creat/colimycin-containing compound medicine for livestock and fowl | |
| CN103908670A (en) | Compound composition for treating livestock escherichia coli infection disease | |
| CN103933543A (en) | Method for treating Escherichia coli infection diseases by using creat and colimycin | |
| CN104337847A (en) | Compound medicine containing bracken and fosfomycin for livestock | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN103933085B (en) | The application of Herba Andrographitis and phosphonomycin in the compound medicine for preparing treatment livestock and poultry coli-infection disease | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN104435011A (en) | Compound medicine containing herba pteridis multifidae and beta-lactam antibiotics drugs for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140730 |